Close Menu

gastric cancer

Using gene expression data combined with bioinformatic analyses, scientists at the University of Georgia and China's Jilin University are developing a urine-based protein biomarker test for gastric cancer that they hope to offer as a direct-to-consumer diagnostic.

The Danish firm received FDA clearance to expand the intended use of its HercepTest and HER2 FISH pharmDx Kit to include patients with metastatic gastric or stomach cancer.

Recently, Mao Mao, a research fellow at Pfizer Oncology Research who is working on several different cancer sequencing projects, spoke to In Sequence about the company's use of sequencing in drug development and the hurdles that still remain in implementing the technology in pharmaceutical research.

A University of Michigan team identified gene fusions in the RAF kinase pathway in prostate cancer, gastric cancer, and melanoma. The researchers said the pathway could potentially be targeted by drugs that are currently in development.

Through the formation of the Asian Cancer Research Group, Eli Lily, Merck, and Pfizer have also committed "to create one of the most extensive pharmacogenomic cancer databases known to date."

Genetic Technologies will distribute the ResponseDX tests in Australia and in five SE Asian Nations.

Indivumed and Georgetown have already established a biobank and clinical database for analyzing tumor specimens to improve cancer diagnostics.

Dako's HER-2 tests may be used as companion diagnostics for Herceptin in treating stomach cancer.

Pharmacogenomics studies presented at the American Association for Cancer Research's annual meeting in Denver, Colo.

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.